Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

4basebio Plc (4BB) Share Price

Price 900.00p on 13-08-2025 at 18:15:08
Change 0.00p 0%
Buy 930.00p
Sell 870.00p
Last Trade: Unknown 1,566.00 at 900.00p
Day's Volume: 3,791
Last Close: 900.00p
Open: 900.00p
ISIN: GB00BMCLYF79
Day's Range 900.00p - 900.00p
52wk Range: 895.00p - 1,500.00p
Market Capitalisation: £139.36m
VWAP: 887.43366p
Shares in Issue: 15.48m

4basebio Plc (4BB) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Unknown* 1,566 900.00p Negotiated Trade
15:02:18 - 13-Aug-25
Unknown* 1,572 872.00p Negotiated Trade
15:01:59 - 13-Aug-25
Sell* 150 873.00p Ordinary
10:35:02 - 13-Aug-25
Buy* 10 906.00p Ordinary
09:50:55 - 13-Aug-25
Unknown* 434 900.00p Ordinary
09:45:28 - 13-Aug-25
Sell* 3 873.00p Ordinary
08:04:06 - 13-Aug-25
Buy* 56 908.00p Ordinary
08:00:07 - 13-Aug-25
Sell* 378 879.00p Ordinary
16:28:52 - 12-Aug-25
Unknown* 1,700 870.00p Negotiated Trade
16:20:47 - 12-Aug-25
Unknown* 1,300 900.00p Ordinary
15:46:22 - 12-Aug-25
See more 4basebio Plc trades

4basebio Plc (4BB) Share Price History

Time period:
to
Date Open High Low Close Volume
13th Aug 2025 (Wed) 900.00 900.00 900.00 900.00 3,791
12th Aug 2025 (Tue) 940.00 940.00 895.00 900.00 5,654
11th Aug 2025 (Mon) 970.00 970.00 960.00 960.00 6,847
8th Aug 2025 (Fri) 970.00 970.00 970.00 970.00 275
7th Aug 2025 (Thu) 970.00 1,000.00 1,000.00 1,000.00 797
6th Aug 2025 (Wed) 970.00 970.00 970.00 970.00 0
5th Aug 2025 (Tue) 930.00 1,000.00 930.00 1,000.00 7
4th Aug 2025 (Mon) 970.00 970.00 940.00 970.00 140
1st Aug 2025 (Fri) 970.00 970.00 970.00 970.00 448
31st Jul 2025 (Thu) 970.00 970.00 920.00 970.00 1,598
30th Jul 2025 (Wed) 970.00 970.00 970.00 970.00 1,235
29th Jul 2025 (Tue) 970.00 970.00 970.00 970.00 0
28th Jul 2025 (Mon) 970.00 970.00 970.00 970.00 19
25th Jul 2025 (Fri) 970.00 970.00 970.00 970.00 2,400
24th Jul 2025 (Thu) 965.00 1,020.00 1,020.00 970.00 411
23rd Jul 2025 (Wed) 965.00 965.00 965.00 965.00 408
22nd Jul 2025 (Tue) 965.00 965.00 965.00 965.00 0
21st Jul 2025 (Mon) 985.00 950.00 950.00 950.00 5,178
18th Jul 2025 (Fri) 985.00 970.00 970.00 985.00 2,504
17th Jul 2025 (Thu) 990.00 990.00 985.00 985.00 4,339
16th Jul 2025 (Wed) 1,000.00 1,000.00 980.00 990.00 7,490
15th Jul 2025 (Tue) 1,000.00 1,000.00 1,000.00 1,000.00 4
14th Jul 2025 (Mon) 1,000.00 1,000.00 1,000.00 1,000.00 96
See more 4basebio Plc price history

4basebio Plc (4BB) Regulatory News

Date Source Headline
22nd Jul 2025 7:00 am PRN Employee Long Term Incentive Plan and Issue of Equity
8th Jul 2025 10:30 am PRN Director Appointment, Board Change
3rd Jul 2025 7:00 am PRN Holding(s) in Company
3rd Jul 2025 7:00 am PRN Holding(s) in Company
2nd Jul 2025 7:00 am PRN Holding(s) in Company
2nd Jul 2025 7:00 am PRN Holding(s) in Company
27th Jun 2025 6:05 pm PRN Result of AGM
25th Jun 2025 7:00 am PRN Exercise of Options
17th Jun 2025 7:00 am PRN Holding(s) in Company
17th Jun 2025 7:00 am PRN Holding(s) in Company
See more 4basebio Plc regulatory news

4basebio Plc (4BB) Share News

UK shareholder meetings calendar - next 7 days

20th Jun 2025 12:02

Read More

4basebio expects to sustain DNA sales growth momentum in 2025

27th May 2025 11:57

(Alliance News) - 4basebio on Tuesday reported a wider pretax loss in 2024, despite higher revenue, and said it is optimistic about the year to come. Read More

IN BRIEF: 4basebio hits "critical milestone" as it secures GMP licence

2nd Apr 2025 09:51

4basebio PLC - Cambridge, England-based life sciences company and manufacturer of synthetic DNA products - Secures good manufacturing practice, or GMP, certification for its UK DNA manufacturing facility from the UK Medicines & Healthcare Products Regulatory Agency. This authorises it to manufacture and supply investigational medicinal product drug substance and critical starting biological medicinal materials used in advanced therapy medicinal products from its Cambridge facility, says the firm. Adds that the certification strengthens its position in the advanced therapeutics field and progresses it towards commercialisation and patient care for a range of advanced therapies. Chief Executive Heikki Lanckriet says: "Achieving GMP certification is a critical milestone for 4basebio, validates our ability to supply synthetic DNA for clinical applications and underscores the hard work and innovation of our team and sets the stage for the next phase of growth for the company." Read More

IN BRIEF: 4basebio names Gabe Longoria as new chief commercial officer

8th Jan 2025 11:47

4basebio PLC - Cambridge, England-based life sciences company and manufacturer of synthetic DNA products - Names Gabe Longoria as the new chief commercial officer. Longoria was previously CCO at Astrea Bioseparations Ltd. The appointment follows a GBP40 million investment into 4basebio by Elevate Medical Technologies and M&G Investment Management Ltd, which completed in November. This is a "key milestone" for the company. Read More

IN BRIEF: 4basebio to supply synthetic DNA for mRNA vaccine program

10th Apr 2024 11:21

4basebio PLC - Cambridge, England-based life sciences company and manufacturer of synthetic DNA products - Announces the supply of its HQ synthetic DNA to an unnamed "Tier 1 pharma company". Says the client will use the synthetic DNA in late preclinical studies for an mRNA vaccine program. Financial details of the contract were not provided by 4basebio. Read More

See more 4basebio Plc news
FTSE 100 Latest
Value9,165.23
Change17.42

Login to your account

Forgot Password?

Not Registered